| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | dabrafenib | GDSC1000 | pan-cancer | AAC | 0.15 | 3e-05 |
| mRNA | tivantinib | CTRPv2 | pan-cancer | AAC | -0.21 | 3e-05 |
| mRNA | LRRK2-IN-1 | CTRPv2 | pan-cancer | AAC | -0.17 | 4e-05 |
| mRNA | THZ-2-102-1 | GDSC1000 | pan-cancer | AAC | -0.14 | 4e-05 |
| mRNA | I-BET151 | CTRPv2 | pan-cancer | AAC | -0.14 | 6e-05 |
| mRNA | PHA-793887 | CTRPv2 | pan-cancer | AAC | -0.15 | 7e-05 |
| mRNA | nakiterpiosin | CTRPv2 | pan-cancer | AAC | -0.15 | 7e-05 |
| mRNA | AT-7519 | GDSC1000 | pan-cancer | AAC | -0.14 | 7e-05 |
| mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.17 | 7e-05 |
| mRNA | YM-155 | CTRPv2 | pan-cancer | AAC | -0.17 | 8e-05 |